C12N 2770/24211
Hepacivirus
Official title: Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
C12N2770/24211 (Hepacivirus) appears on 881 US grants and 1,040 published applications in this corpus.
Search patents in C12N- Granted patents
- 881
- Published applications
- 1,040
- Assignees
- 464
- Inventors
- 1,833
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 5 | 0 |
| 1994 | 10 | 0 |
| 1995 | 7 | 0 |
| 1996 | 12 | 0 |
| 1997 | 19 | 0 |
| 1998 | 44 | 0 |
| 1999 | 48 | 0 |
| 2000 | 41 | 0 |
| 2001 | 44 | 4 |
| 2002 | 25 | 51 |
| 2003 | 45 | 92 |
| 2004 | 25 | 55 |
| 2005 | 29 | 63 |
| 2006 | 39 | 61 |
| 2007 | 39 | 48 |
| 2008 | 36 | 56 |
| 2009 | 20 | 72 |
| 2010 | 37 | 83 |
| 2011 | 34 | 77 |
| 2012 | 33 | 55 |
| 2013 | 39 | 38 |
| 2014 | 34 | 42 |
| 2015 | 34 | 36 |
| 2016 | 25 | 31 |
| 2017 | 29 | 27 |
| 2018 | 22 | 20 |
| 2019 | 17 | 11 |
| 2020 | 13 | 23 |
| 2021 | 16 | 16 |
| 2022 | 11 | 20 |
| 2023 | 10 | 19 |
| 2024 | 10 | 18 |
| 2025 | 10 | 15 |
| 2026 | 3 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/24222New viral proteins or individual genes, new structural or functional aspects ofIndexing code683
- C12N 2770/24234Use of virus or viral component as vaccineIndexing code246
- C12N 2770/24221Viruses as suchIndexing code82
- C12N 2770/24241Use of virus, viral particle or viral elements as a vectorIndexing code49
- C12N 2770/24251Methods of production or purification of viral materialIndexing code46
- C12N 2770/24261Methods of inactivation or attenuationIndexing code20
- C12N 2770/24271Demonstrated in vivo effectIndexing code15
- C12N 2770/24223Virus like particles [vlp]Indexing code12
All 12 subgroupsShow fewer
Recent patents
- Compositions and methods for membrane protein structure determination12 May 2026US 12,624,092 B2The Regents of the University of Michigan
- Immunogenic compositions of hepatitis c virus and uses thereof14 Apr 2026US 12,599,661 B2
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- Method of purifying whole virus particles16 Dec 2025US 12,497,598 B2Hvidovre Hospital
- Chimeric antigen receptor polypeptides and methods of using same18 Nov 2025US 12,473,344 B2The Board of Trustees of the Leland Stanford Junior University
- High-yield genotype 1a, 2a and 3a hcv10 Sep 2026US 2026/0263580 A1Hvidovre Hospital
- Human broadly neutralizing monoclonal antibodies associated with hepatitisc virus clearance10 Sep 2026US 2026/0265351 A1The Johns Hopkins University
- Zika and hcv attenuated viruses and use thereof2 Jul 2026US 2026/0185060 A1Bar-Ilan University
- Chimeric Antigen Receptor Polypeptides and Methods of Using Same16 Apr 2026US 2026/0103504 A1The Board of Trustees of the Leland Stanford Junior University
- Regulatable Cell Surface Receptors and Related Compositions and Methods19 Mar 2026US 2026/0078164 A1The Board of Trustees of the Leland Stanford Junior University
Most cited
By later US patents
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998
- HCV immunoassays employing C domain antigens147US 5,350,671 AChiron Corporation · 1994
- Gas inlet for a plurality of reactant gases into reaction vessel142US 5,441,703 AAixtron SE · 1995
- Compositions and methods for delivery of genetic material132US 5,962,428 AApollon Inc. · 1999
- Methods, primers and probes for detection of hepatitis C and novel variants107US 5,527,669 AHoffmann-La Roche Inc. · 1996